Latest available resultsQuarter ended June 30, 202610-Q · August 4, 2026
Filed with the SECIDEXX LABORATORIES INC /DE
IDXXPharma & biotech
Next reportNovember 2, 2026pre-market · Analyst forecast 3.813 $/share
Revenue
$1.22B
▲ +9.7% vs prior year% YoY
Net income
$338.41M
▲ +15.1% vs prior year% YoY
EPS
4.27$
▲ +17.6% vs prior year% YoY
Net margin
27.8%
▲ +1.3 percentage points vs prior year pp YoY
Revenue▲ +9.7 %
Margins (% of revenue)GrossOperatingNet
Net income▲ +15.1 %
EPS▲ +17.6 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $1.22B | |
| Gross profit | $779.09M | 64.0 % |
| Operating income | $425.57M | 35.0 % |
| Net income | $338.41M | 27.8 % |
| R&D | $65.43M | 5.4 % |
| EPS (diluted) | 4.27 $ | |
| Balance sheet | ||
| Assets | $3.44B | |
| Liabilities | $1.83B | |
| Equity | $1.61B | |
| Cash | $196.93M | |
| Capital | ||
| Shares outstanding | 78.78M | as of 2026-07-31 |
| Public float | — | |